Alembic Pharmaceuticals
-
January 10, 2022, Monday
Alembic Pharmaceuticals gets USFDA nod to market generic product
Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market generic Dronedarone ...
-
January 08, 2022, Saturday
Alembic Pharma gets tentative USFDA approval for depressive disorder drug
Alembic Pharmaceuticals Ltd on Friday said it has received tentative approval from the US health regulator for its generic ...
-
January 07, 2022, Friday
Stocks to Watch: RIL, Wockhardt, IDBI Bk, SJVN, Titan, DMart, FMCG, Pharma
Pharma shares may be in focus as India's apex health research organization ICMR has raised concerns around the safety for use of ...
-
January 06, 2022, Thursday
Alembic Pharma gets USFDA nod for generic drug to treat Parkinson's disease
Alembic Pharmaceuticals on Thursday said it has received final approval from the US health regulator for its generic Entacapone ...
-
January 04, 2022, Tuesday
Alembic gets USFDA nod for generic drug to treat bacterial infections
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application ...
-
December 08, 2021, Wednesday
Alembic gets USFDA nod for generic hypertension treatment drug
Alembic said it has so far received 15 product approvals this year
-
December 01, 2021, Wednesday
Glenmark, Alembic, Cipla: Pharma stocks on a booster dose this December
Select pharma stocks look good on the technical charts and may jump up to 15 per cent in December. On the fundamental side, fears ...
-
November 23, 2021, Tuesday
Alembic Pharma gets USFDA nod for formoterol fumarate inhalation solution
Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US Food & Drug Administration (USFDA) for its ...
-
November 11, 2021, Thursday
Alembic Pharma dips 5% on disappointing September quarter results
Alembic Pharma said that the USFDA recently inspected the company's injectable facility (F-3) site and issued Form 483 with 10 ...
-
November 10, 2021, Wednesday
Alembic Pharma's Q2 net halves to Rs 169 cr as US biz takes 40% dip
Revenue from operations too fell by 11 per cent to Rs 1,292.32 crore in Q2 of FY22
